Smart Blood Analytics Swiss has secured the European Medical Device Regulation (EU-MDR) certification for its VIRUS versus BACTERIA Clinical Decision Support Software.

This certification is a forward step in the fight against antimicrobial resistance (AMR), a growing global health concern.

AMR is exacerbated by the misuse and overuse of antibiotics. This not only threatens public health but also places a heavy financial burden on healthcare systems.

The VIRUS versus BACTERIA software aims to address this issue by accurately distinguishing between viral and bacterial infections, enabling physicians to prescribe the most effective treatments.

The software uses 17 routine blood parameters, biological sex, and age to differentiate infections.

Its effectiveness and accuracy were recently highlighted in a Heliyon journal article.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the widespread availability of routine blood testing, VIRUS versus BACTERIA can enhance the diagnostic capabilities of doctors globally, particularly in scenarios where other blood markers have limited diagnostic utility.

Smart Blood Analytics Swiss CEO Dr Marko Notar said: “This achievement shows our commitment to advancing healthcare through innovation.

“By providing clinicians with a precise tool to differentiate between viral and bacterial infections, we aim to empower doctors with more information and help them in their decision of antibiotic prescriptions. This contributes to more effective healthcare practices.”

The inspiration for VIRUS versus BACTERIA came from the 2022 G20 Bali summit, which issued a call to action on AMR.

This summit underscored the critical need for innovative solutions to address the silent pandemic of AMR.

The EU-MDR certification process is rigorous, ensuring that medical devices meet very high standards of safety, quality, and compliance with EU regulations.

With its certification, VIRUS versus BACTERIA is now poised to become a tool for healthcare professionals worldwide.

Its user-friendly interface is designed to empower practitioners in their efforts to use antibiotics rationally and effectively to combat the threat of antimicrobial resistance.